FDA draws patients into alosetron risk management.
Miller
J L
JL
D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use*; D017091:Colitis, Ischemic / Q000139:chemically induced; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced; D000075202:Contraindications; D004348:Drug Labeling; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D012308:Risk Management; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron